Curriculum Vitaes

ABE KAZUHO

  (阿部 和穂)

Profile Information

Affiliation
Faculty of Pharmacy Department of Pharmaceutical Sciences, Musashino University
Degree
博士(東京大学)
修士(東京大学大学院)

J-GLOBAL ID
200901002682792583
researchmap Member ID
1000013647

External link

Research Interests

 2

Committee Memberships

 2

Papers

 3
  • Hiroko Ushikubo, Sayaka Watanabe, Yui Tanimoto, Kazuho Abe, Aiki Hiza, Takahiro Ogawa, Tomohiro Asakawa, Toshiyuki Kan, Tatsuhiro Akaishi
    NEUROSCIENCE LETTERS, 513(1) 51-56, Mar, 2012  Peer-reviewed
    The natural flavonoid fisetin (3,3',4',7-tetrahydroxyflavone) is neurotrophic and prevents fibril formation of amyloid beta protein (A beta). It is a promising lead compound for the development of therapeutic drugs for Alzheimer's disease. To find even more effective drugs based on the structure of fisetin, we synthesized a series of fisetin analogues lacking the 7-hydroxyl group and compared their effects on A beta fibril formation determined by the thioflavin T fluorescence assay. 3,3',4'-Trihydroxyflavone and 3',4'-dihydroxyflavone inhibited A beta fibril formation more potently than fisetin or 3',4',7-trihydroxyflavone, suggesting that the 7-hydroxy group is not necessary for anti-amyloidogenic activity. 3,3',4',5'-Tetrahydroxyflavone and 3',4',5'-trihydroxyflavone inhibited A beta fibril formation far more potently than 3,3',4'-trihydroxyflavone and 3',4'-dihydroxyflavone, suggesting that 3',4',5'-trihydroxyl group of the B ring is crucial for the anti-amyloidogenic activity of flavonoids. Based on the structure-activity relationship, we synthesized 3,3',4',5,5'-pentahydroxyflavone, and confirmed that this compound is the most potent inhibitor of A beta fibril formation among fisetin analogues that have been tested. Cytotoxicity assay using rat hippocampal neuron cultures demonstrated that A beta preincubated with 3,3',4',5,5'-pentahydroxyflavone was significantly less toxic than A beta preincubated with vehicle. 3,3',4',5,5'-Pentahydroxyflavone could be a new therapeutic drug candidate for the treatment of Alzheimer's disease. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
  • Qi Chen, Marguerite Prior, Richard Dargusch, Amanda Roberts, Roland Riek, Cedric Eichmann, Chandramouli Chiruta, Tatsuhiro Akaishi, Kazuho Abe, Pamela Maher, David Schubert
    PLOS ONE, 6(12) e27865, Dec, 2011  Peer-reviewed
    Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer's disease (AD), the focus is the amyloid beta peptide (A beta) that mediates familial Alzheimer's disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.
  • Takuro Ueki, Tatsuhiro Akaishi, Hidenobu Okumura, Tsuneo Morioka, Kazuho Abe
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 115(2) 254-257, Feb, 2011  Peer-reviewed
    We compared the effects of the extract from fruits of Nandina domestica THUNBERG (NDE) and its constituents, higenamine and nantenine, on contractile responses in isolated guineapig trachea. NDE (1 mg/ml) caused biphasic relaxation of the trachea precontracted with high-K(+) stimulation: the fast component was blocked by propranolol and mimicked by higenamine; and the slow was resistant to propranolol and mimicked by nantenine. Ca(2+)-induced contraction under high-K(+) stimulation was antagonized by nantenine or NDE + propranolol. These results suggest that NDE relaxes the trachea quickly through beta-adrenoceptor stimulation by higenamine and slowly through Ca(2+) antagonism by nantenine.

Misc.

 131
  • Muneo Tsukiyama, Takuro Ueki, Yoichi Yasuda, Hiroko Kikuchi, Tatsuhiro Akaishi, Hidenobu Okumura, Kazuho Abe
    PLANTA MEDICA, 75(13) 1393-1399, Oct, 2009  
    The fruit of Nandina domestica Thunberg (ND, Berberidaceae) has been used to improve cough and breathing difficulties in Japan for many years, but very little is known about the constituent of ND responsible for this effect. We have recently reported that the crude extract from ND (NDE) inhibits histamine- and serotonin-induced contraction of isolated guinea pig trachea, and the inhibitory activity was not explained by nantenine, a well-known alkaloid isolated from ND. To explore other constituent(s)(s) of NDE with tracheal smooth muscle relaxant activity, we fractionated NDE and assessed the pharmacological effects of the fractions using isolated guinea pig tracheal ring preparations. NDE was introduced into a polyaromatic absorbent resin column and stepwise eluted to yield five fractions, among which only the 40% methanol fraction was active in relaxing tracheal smooth muscle precontracted with histamine. Further separation of the 40% methanol fraction with high-performance liquid chromatography yielded multiple subfractions, one of which was remarkably active in relaxing histamine-precontracted trachea. Chemical analysis with a time-of-flight mass spectrometer and nuclear magnetic resonance spectrometer identified the constituent of the most active subfraction as higenamine, a benzyltetrahydroisoquinoline alkaloid. The potency and efficacy of the active constituent from NDE in relaxing trachea were almost equivalent to synthetic higenamine. In addition, the effect of the active constituent from NDE was competitively inhibited by the selective beta(2)-adrenoceptor antagonist ICI 118,551. These results indicate that the major Constituent responsible for the effect of NDE is higenamine, which probably causes the tracheal relaxation through stimulation of beta(2) adrenoceptors.
  • Kazuho Abe, Taiki Fujimoto, Tatsuhiro Akaishi, Miwa Misawa
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 33(3) 552-556, Apr, 2009  
    We have previously found that the induction of hippocampal long-term potentiation (LTP) is modulated by neuron activities in the basolateral amygdala (BLA). However, little is known about what neurotransmitter system in the BLA contributes to modulation of hippocampal LTP. In the present study, we investigated possible involvement of BLA dopaminergic system in the induction of UP at the perforant path (PP)-dentate gyrus (DG) granule cell synapses of anesthetized rats. The induction of PP-DG LTP was significantly attenuated by intra-BLA injection of the D(1) receptor antagonist SCH23390 (2 or 6 nmol) or the D(2) receptor antagonists, chlorpromazine (30 or 100 nmol) or haloperidol (4.4 or 13.3 nmol). The effects of SCH23390 and haloperidol were abolished by concomitant intra-BLA injection of the D(1) receptor agonist SKF38393 (17 nmol) and the D(2) receptor agonist quinpirole (3 nmol), respectively. Furthermore, lesioning with 6-hydroxydopamine of the ventral tegmental area, the origin of the dopaminergic system projecting to the BLA, resulted in attenuated PP-DG LTP, which was restored by intra-BLA injection of SKF38393 or quipirole. These results suggest that the induction of PP-DG UP is promoted by the BLA dopaminergic system via both D(1) and D(2) receptors. (C) 2009 Elsevier Inc. All rights reserved.
  • Kazuho Abe, Taiki Fujimoto, Yoshiaki Niikura, Tatsuhiro Akaishi, Miwa Misawa
    EUROPEAN JOURNAL OF PHARMACOLOGY, 606(1-3) 90-93, Mar, 2009  
    We have previously found that the induction of long-term potentiation in the synaptic pathway from the basolateral amygdala to the dentate gyros (BLA-DG LTP) is regulated by L-type Ca2+ channels, dopamine D-2 receptors and GABAergic inhibition. In the present study, we investigated possible relations among the three mechanisms by using anesthetized rats. Blockade of GABAergic inhibition with picrotoxin abolished both the inhibitory effect of the dopamine D-2 receptor antagonist chlorpromazine and the promoting effect of the dopamine D-2 receptor agonist quinpirole on the induction of BLA-DG LTP. However, the inhibitory effect of the L-type Ca2+ channel blocker verapamil on BLA-DG LTP was not affected by picrotoxin. These results suggest that the role of dopamine D-2 receptors in the induction of BLA-DG LTP is modulatory and depends on GABAergic inhibition, whereas the role of L-type Ca2+ channels is fundamental. (C) 2009 Elsevier B.V. All rights reserved.
  • Kazuho Abe, Taiki Fujimoto, Tatsuhiro Akaishi, Miwa Misawa
    NEUROSCIENCE LETTERS, 451(1) 65-68, Feb, 2009  
    We have previously found that the induction of hippocampal long-term potentiation (LTP) is modulated by neuron activities in the basolateral amygdala (BLA). However, little is known about what neurotransmitter system in the BLA contributes to modulation of hippocampal LTP. In the present study, we investigated possible involvement of BLA serotonergic system in the induction of LTP at the perforant path (PP)-dentate gyrus (DG) granule cell synapses of anesthetized rats. The induction of PP-DG LTP was significantly inhibited by intra-BLA injection of the 5-HT2 receptor antagonist cinanserin (25-50 nmol), but not by intra-BLA injection of the 5-HT1.7 receptor antagonist methiothepin (50 nmol), the 5-HT3 receptor antagonist ondansetron (50 nmol) or the 5-HT4 receptor antagonist RS23597-190 (100 nmol). In addition, intra-BLA injection of the 5-HT2C receptor agonist MK212 (50 nmol) facilitated the induction of PP-DG LTP. These results suggest that the induction of PP-DG LTP is promoted by activation of 5-HT2C receptors in the BLA. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
  • Kazuho Abe, Yoshiaki Niikura, Taiki Fujimoto, Tatsuhiro Akaishi, Miwa Misawa
    NEUROPHARMACOLOGY, 55(8) 1419-1424, Dec, 2008  
    We have previously found that synaptic pathway from the basolateral amygdala (BLA) to the dentate gyrus (DG) displays N-methyl-D-aspartate (NMDA) receptor-independent form of long-term potentiation (LTP), which should be a valuable model for elucidating neural mechanisms linking emotion and memory. To explore its cellular mechanisms, we investigated possible involvement of the beta-adrenergic, muscarinic cholinergic and dopaminergic systems on UP in this pathway of anesthetized rats. The induction of BLA-DG LTP was not affected by administration of the beta-adrenoceptor antagonist propranolol (50-150 nmol, i.c.v.), the muscarinic receptor antagonist scopolamine (2-6 mg/kg, i.p.), the cholinesterase inhibitor physostigmine (50 nmol, i.c.v.) or the dopamine D-1 receptor antagonist SCH23390 (100 nmol, i.c.v.), but Significantly inhibited by the dopamine D-2 receptor antagonists, chlorpromazine (15 nmol, i.c.v.) and haloperidol (0.15-0.5 mg/kg, i.p.), and significantly promoted by the dopamine D-2 receptor agonist quinpirole (78 nmol, i.c.v.). Furthermore, lesioning with 6-hydroxydopamine of the ventral tegmental area (VTA), the origin of mesolimbic dopaminergic neurons, resulted in attenuated BLA-DG LTP. These results Suggest that the D-2-dopaminergic system, but not the beta-adrenergic, muscarinic or D-1-dopaminergic system, is involved in the induction of BLA-DG LTR In addition, inhibition of BLA-DG UP by haloperidol or VIA lesion was abolished by blockade of GABAergic inhibition with picrotoxin. It is probable that the D-2-dopaminergic system promotes the induction of BLA-DG LTP by Suppressing GABAergic inhibition. (C) 2008 Elsevier Ltd. All rights reserved.

Books and Other Publications

 24
  • 阿部和穂, 村上泰興, 鈴木順子 (Role: Joint author)
    評言社, Jun, 2009
    平成21年春に実施された94回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 阿部和穂, 三澤美和, 千葉義彦, 松岡隆, 砂金信義, 宇留野強, 小島周二 (Role: Joint author)
    評言社, Apr, 2009
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2010年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」などについて分担執筆した。
  • 阿部和穂, 村上泰興, 上田晴久 (Role: Joint author)
    評言社, Jun, 2008
    平成20年春に実施された93回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 阿部和穂, 三澤美和, 千葉義彦, 松岡隆, 砂金信義, 宇留野強, 小島周二 (Role: Joint author)
    評言社, Apr, 2008
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2009年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」などについて分担執筆した。
  • 阿部和穂, 村上泰興, 上田晴久 (Role: Joint author)
    評言社, Jun, 2007
    平成19年春に実施された92回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 阿部和穂, 三澤美和, 千葉義彦, 松岡隆, 砂金信義, 宇留野強, 小島周二 (Role: Joint author)
    評言社, Apr, 2007
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2008年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」について分担執筆した。
  • 阿部和穂石井邦雄, 伊藤幹雄 (Role: Joint author)
    廣川書店, Mar, 2007
    薬剤師国家試験ガイドラインに沿った医療薬学・薬理学の教科書。当人は「平滑筋に作用する薬物」について分担執筆した。
  • 阿部和穂, 三澤美和, 千葉義彦, 松岡隆, 砂金信義, 宇留野強, 小島周二 (Role: Joint author)
    評言社, Apr, 2006
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2007年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」について分担執筆した。
  • 阿部和穂, 小池勝夫, 萩原政彦 (Role: Joint author)
    朝倉書店, Mar, 2006
    薬剤師国家試験ガイドラインに沿った医療薬学・薬理学の教科書。当人は「オータコイド」「呼吸器系に作用する薬物」について分担執筆した。
  • 阿部和穂, 齋藤洋 (Role: Joint author)
    シーエムシー出版, Mar, 2006
    認知症治療薬開発の最新動向をまとめた専門書。当人は編者として企画・構成に携わるとともに、半分近くの執筆も担当した。
  • 阿部和穂, 村上泰興, 上田晴久 (Role: Joint author)
    評言社, Mar, 2006
    平成18年春に実施された91回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 阿部和穂, 三澤美和, 松岡隆, 砂金信義, 宇留野強, 小島周二 (Role: Joint author)
    評言社, Jul, 2005
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、2006年春の国家試験対策として必要な知識をまとめた参考書。当人は「中枢神経系に作用する薬物」「オータコイド」「病原生物に作用する薬物」について分担執筆した。
  • 阿部和穂, 村上泰興, 上田晴久 (Role: Joint author)
    評言社薬学教育センター, May, 2005
    平成17年春に実施された90回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の作用に関する出題30問について解説を執筆した。
  • 三澤美和, 宇留野強, 松岡隆, 砂金信義, 小島周二 (Role: Joint author)
    評言社, Jun, 2004
    薬剤師国家試験ガイドラインの医療薬学・薬理学の分野について、国家試験対策として必要な知識をまとめた参考書。当人は、「中枢神経系に対する薬物」「オータコイド」「病原生物に作用する薬物」について分担執筆した。
  • 村上泰興, 上田晴久 (Role: Joint author)
    評言社, May, 2004
    平成16年春に実施された89回薬剤師国家試験問題の解答と解説を記した本。当人は医療薬学分野の医薬品の有効性と安全性に関する出題28問について、解説を執筆した。
  • 編者, 三澤美和, 吉田正, 著者, 阿部和穂 (Role: Joint author)
    丸善, Aug, 2003
    各種疾患患者のカルテに基づき薬物治療法の実際について解説。
  • 編者, 宇留野強, 著者, 宇留野強, 阿部和穂 (Role: Joint author)
    評言社薬学教育センター, Jun, 2003
    医療薬学分野(医薬品の作用機序:薬理学)のうち、中枢神経系に作用する薬物、オータコイド、病原生物に作用する薬物に関する内容について、89回薬剤師国家試験対策に必要な知識を詳細解説。(総頁数771頁中、P115~P215、P537~P586)
  • 著者 宇留野強, 阿部和穂 (Role: Joint author)
    評言社薬学教育センター, May, 2003
    88回薬剤師国家試験問題のうち、医薬品の作用機序に関する出題(薬理学)部分について、解説および解答を執筆。全271ページ中P144~P177を担当
  • 編者 宇留野強著者, 宇留野強, 阿部和穂 (Role: Joint author)
    日本コンサルタントグループ, Jun, 2002
    医療薬学分野(医薬品の作用機序:薬理学)のうち、中枢神経系に作用する薬物、オータコイド、病原生物に作用する薬物に関する内容について、88回薬剤師国家試験対策に必要な知識を詳細解説。全771ページ中P115~P215, P537~586を担当
  • 著者 宇留野強, 阿部和穂 (Role: Joint author)
    日本コンサルタントグループ, May, 2002
    87回薬剤師国家試験問題のうち、医薬品の作用機序に関する出題(薬理学)部分について、解説および解答を執筆。全271ページ中P134~P169を担当
  • 編者 宇留野強著者, 宇留野強, 阿部和穂 (Role: Joint author)
    日本コンサルタントグループ, Jul, 2001
    医療薬学分野(医薬品の作用機序:薬理学)のうち、中枢神経系に作用する薬物、オータコイド、病原生物に作用する薬物に関する内容について、87回薬剤師国家試験対策に必要な知識を詳細解説。全858ページ中P139~P249, P629~685を担当
  • 著者 宇留野強, 阿部和穂 (Role: Joint author)
    日本コンサルタントグループ, May, 2001
    全306ページ中P138~P176, P295~297を担当86回薬剤師国家試験問題のうち、医薬品の作用機序に関する出題(薬理学)部分について、解説および解答を執筆。
  • 編者 宇留野強著者, 宇留野強, 阿部和穂 (Role: Joint author)
    日本コンサルタントグループ, Jul, 2000
    医療薬学分野(医薬品の作用機序:薬理学)のうち、中枢神経系に作用する薬物、オータコイド、病原生物に作用する薬物に関する内容について、86回薬剤師国家試験対策に必要な知識を詳細解説。全879ページ中P151~P269, P707~770を担当
  • 宇留野強, 阿部和穂 (Role: Joint author)
    日本コンサルタントグループ, Jun, 2000
    85回薬剤師国家試験問題のうち、医薬品の作用機序に関する出題(薬理学)部分について、解説および解答を執筆。全305ページ中P138~P180, P297~298を担当